Diagnostic and prognostic values of serum activin-a levels in patients with acute respiratory distress syndrome

Abstract

BackgroundWe aimed to evaluate whether serum activin-A levels are elevated and have any value in predicting severity and prognosis in acute respiratory distress syndrome (ARDS).MethodsRetrospective cohort study was performed with patients who were admitted to MICU with diagnosis of ARDS and have serum samples stored within 48h of Intensive care unit (ICU) admission between March 2013 and December 2016 at a single tertiary referral hospital. Serum activin-A levels were measured with ELISA kit, and were compared with those of normal healthy control and non-ARDS sepsis patients.ResultsTotal 97 ARDS patients were included for the study. Levels of Activin-A were elevated in ARDS patients compared to those of healthy controls (Log-transformed activin-A levels 2.890.36 vs. 2.34 +/- 0.11, p<0.001, absolute activin-A levels 1525.6 +/- 1060.98 vs. 225.9 +/- 30.1, p=0.016) and non-ARDS sepsis patients (Log-transformed activin-A levels 2.89 +/- 0.36 vs. 2.73 +/- 0.34, p=0.002, Absolute activin-A levels 1525.6 +/- 1060.98 vs. 754.8 +/- 123.5pg/mL, p=0.036). When excluding five outliers with extremely high activin-A levels, activin-A showed statistically significant correlation with in-hospital mortalities (In-hospital survivors 676.2 +/- 407 vs. non-survivors 897.9 +/- 561.9pg/mL, p=0.047). In predicting in-hospital mortality, serum activin-A concentrations showed superior area under curve compared to that of Acute physiologic and chronic health evaluation II scores (0.653; 95% CI [0541, 0.765] vs. 0.591, 95% CI [0.471, 0.710]). With cut-off level of 708pg/mL, those with high serum activin-A levels had more than twofold increased risk of in-hospital mortalities. However, those relations were missing when outliers were in.Conclusions Serum activin-A levels in ARDS patients are elevated. However, its levels are weakly associated with ARDS outcomes.